Brief: Antares Therapeutics Enters Agreement With Novartis To Discover, Develop And Commercialize First-In-Class Cancer Therapies
Wed 12:24
BRIEF-Antares Therapeutics Enters Agreement With Novartis To Discover, Develop And Commercialize First-In-Class Cancer Therapies June 24 (Reuters) - Novartis AG NOVN.S:
ANTARES THERAPEUTICS ENTERS AGREEMENT WITH NOVARTIS TO DISCOVER, DEVELOP AND COMMERCIALIZE FIRST-IN-CLASS CANCER THERAPIES
ANTARES: TO RECEIVE $105M UPFRONT IS ELIGIBLE FOR UP TO $1.8B IN ADDITIONAL OPTION EXERCISE, DEVELOPMENT, REGULATORY, AND COMMERCIAL MILESTONES
Source text: ID:nBwLYyYxa
Further company coverage: NOVN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Novartis AG
See all newsSwiss pharma at risk of US trade investigation, industry body says
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
Brief: Antares Therapeutics Enters Agreement With Novartis To Discover, Develop And Commercialize First-In-Class Cancer Therapies
Nuvectis gains two experimental drugs in licensing deal with China's Haisco (updated)